# US 2011/0236412 A1 · Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0236412 A1
- Document ID: US20110236412A1
- Status: Published application
- Kind: A1
- Application number: 13/120,539
- Filed: 2009-09-24
- Published: 2011-09-29
- Earliest claimed: 2008-09-24
- Assignees: Stabilitech Ltd.
- Inventors: Jeffrey Drew
- Web page: https://patentgrep.com/patent/US20110236412A1

## CPC

- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 37/04: Immunostimulants
- C07K 14/47: from mammals
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A method for preserving a polypeptide comprises (i) providing an aqueous solution of one or more sugars, a polyethyleneimine and said polypeptide wherein the concentration of polyethyleneimine is 25 μM or less based on the number-average molar mass (Mn) of the polyethyleneimine and the sugar concentration or, if more than one sugar is present, total sugar concentration is greater than 0.1 M; and (ii) drying the solution to form an amorphous solid matrix comprising said polypeptide.

## Claims

### Claim at position 1

1-48. (canceled)

### Claim 49

A method for preserving a polypeptide comprising:
(i) providing an aqueous solution of one or more sugars, a polyethyleneimine and said polypeptide; and
(ii) drying the solution to form an amorphous solid matrix comprising said polypeptide.

### Claim 50 (depends on 49)

The method according to claim 49 wherein the concentration of polyethyleneimine is 25 μM or less based on the number-average molar mass (Mn) of the polyethyleneimine and the sugar concentration or, if more than one sugar is present, total sugar concentration is greater than 0.1 M.

### Claim 51 (depends on 50)

The method according to claim 50 in which
(a) the Mn of the polyethyleneimine is between 20 and 1000 kDa and the concentration of the polyethyleneimine is between 0.001 and 100 nM based on the Mn, and/or
(b) the Mn of the polyethyleneimine is between 1 and 10000 Da and the concentration of the polyethyleneimine is between 0.0001 and 10 μM based on the Mn, and/or
(c) the said concentration of polyethyleneimine is 20 μM or less or less than 500 nM, and/or
(d) the said concentration of polyethyleneimine is 0.025 nM or more or 0.1 nM or more, and/or
(e) the said concentration of polyethyleneimine is between 0.1 nM and 5 μM or between 0.1 nM and 200 nM.

### Claim 52 (depends on 50)

The method according to claim 50 in which
(a) the sugar concentration, or total sugar concentration, is between 0.5 and 2M; and/or
(b) the sugar is sucrose, stachyose, raffinose or a sugar alcohol, or
(c) two or more sugars are present in said aqueous solution, or
(d) two or more sugars are present in said aqueous solution and wherein sucrose is present with another sugar; the concentration of sucrose relative to the other sugar is at a ratio of molar concentrations of between 3:7 and 9:1; and the concentration of polytheyleneimine based on Mn in step (i) is between 0.0025 nM and 5 μM, and/or
(e) the sugars are sucrose and raffinose.

### Claim 53 (depends on 50)

The method according to claim 50 in which
(a) the solution is freeze-dried in step (ii), or
(b) the polypeptide is a hormone, growth factor, peptide or cytokine, or
(c) the polypeptide is a tachykinin peptide, a vasoactive intestinal peptide, a pancreatic polypeptide-related peptide, an opioid peptide or a calcintonin peptide, or
(d) the polypeptide is an antibody or antigen-binding fragment thereof, or
(e) the polypeptide is an antibody or antigen-binding fragment thereof in which the antibody or antigen-binding fragment is a monoclonal antibody or fragment thereof, or
(f) the polypeptide is an antibody or antigen-binding fragment thereof in which the antibody or antigen-binding fragment is a chimeric, humanized or human antibody, or fragment thereof, or
(g) the polypeptide is an antibody or antigen-binding fragment thereof in which the antibody or antigen-binding fragment is a chimeric, humanized or human antibody, or fragment thereof which is an IgG1, IgG2 or IgG4 or antigen-binding fragment thereof, or
(h) the polypeptide is an antibody or antigen-binding fragment which is capable of binding to: (i) tumour necrosis factor α (TNF-α), interleukin-2 (IL-2), interleukin-6 (IL-6), glycoprotein IIb/IIIa, CD33, CD52, CD20, CD11a, CD3, RSV F protein, HER2/neu (erbB2) receptor, vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), anti-TRAILR2 (anti-tumour necrosis factor-related apoptosis-inducing ligand receptor 2), complement system protein C5, α4 integrin or IgE, or (ii) epithelial cell adhesion molecule (EpCAM), mucin-1 (MUC1/Can-Ag), EGFR, CD20, carcinoembryonic antigen (CEA), HER2, CD22, CD33, Lewis Y or prostate-specific membrane antigen (PMSA).

### Claim 54 (depends on 50)

The method according to claim 50 in which the polypeptide is
(a) an enzyme, or
(b) an enzyme which is an oxidoreductase, a transferase, a hydrolase, a lyase, an isomerase or a ligase, or
(c) an enzyme selected from an α-galactosidase, β-galactosidase, luciferase, serine proteinase, endopeptidase, caspase, chymase, chymotrypsin, endopeptidase, granzyme, papain, pancreatic elastase, oryzin, plasmin, renin, subtilisin, thrombin, trypsin, tryptase, urokinase, amylase, xylanase, lipase, transglutaminase, cell-wall-degrading enzyme, glucanase, glucoamylase, coagulating enzyme, milk protein hydrolysate, cell-wall degrading enzyme, coagulating enzyme, lysozyme, fibre-degrading enzyme, phytase, cellulase, hemicellulase, protease, mannanase or glucoamylase, or
(d) a vaccine immunogen, or
(e) a vaccine immunogen which is a full-length viral or bacterial protein, glycoprotein or lipoprotein; or a fragment thereof.

### Claim 55 (depends on 49)

The method according to claim 49 which further comprises providing the resulting dried amorphous solid matrix in the form of a powder in a sealed vial, ampoule or syringe.

### Claim 56

A method for preserving a vaccine immunogen comprising:
(i) providing an aqueous solution of one or more sugars, a polyethyleneimine and said vaccine immunogen; and
(ii) drying the solution to form an amorphous solid matrix comprising said vaccine immunogen.

### Claim 57 (depends on 56)

The method according to claim 56 wherein the concentration of polyethyleneimine is 25 μM or less based on the number-average molar mass (Mn) of the polyethyleneimine and the sugar concentration or, if more than one sugar is present, total sugar concentration is greater than 0.1 M.

### Claim 58 (depends on 57)

The method according to claim 57 in which
(a) the Mn of the polyethyleneimine is between 20 and 1000 kDa and the concentration of the polyethyleneimine is between 0.001 and 100 nM based on the Mn and/or
(b) the Mn of the polyethyleneimine is between 1 and 10000 Da and the concentration of the polyethyleneimine is between 0.0001 and 10 μM based on the Mn, and/or
(c) the said concentration of polyethyleneimine is 20 mM or less or less than 500 nM, and/or
(d) the said concentration of polyethyleneimine is 0.025 nM or more or 0.1 nM or more, and/or
(e) the said concentration of polyethyleneimine is between 0.1 nM and 5 μM or between 0.1 nM and 200 nM.

### Claim 59 (depends on 57)

The method according to claim 57 in which
(a) the sugar concentration, or total sugar concentration, is between 0.5 and 2M, and/or
(b) the sugar is sucrose, stachyose, raffinose or a sugar alcohol, and/or
(c) two or more sugars are present in said aqueous solution, and/or
(d) sucrose is present with another sugar; the concentration of sucrose relative to the other sugar is at a ratio of molar concentrations of between 3:7 and 9:1; and the concentration of polytheyleneimine based on Mn in step (i) is between 0.0025 nM and 5 μM, and/or
(e) the sugars are sucrose and raffinose.

### Claim 60 (depends on 57)

The method according to claim 57 in which the solution is freeze-dried in step (ii).

### Claim 61 (depends on 57)

The method according to claim 57 in which
(a) the vaccine immunogen is a subunit vaccine, conjugate vaccine or toxoid, or
(b) the vaccine immunogen is a subunit vaccine in which the subunit vaccine immunogen is derived from a viral surface protein or viral capsid protein.

### Claim 62 (depends on 56)

The method according to claim 56 further comprising providing the resulting dried amorphous solid matrix in the form of a powder in a sealed vial, ampoule or syringe.

### Claim 63 (depends on 49)

A dry powder comprising preserved polypeptide or vaccine immunogen, obtained by the method as defined in claim 49.

### Claim 64 (depends on 56)

A dry powder comprising preserved polypeptide or vaccine immunogen, obtained by the method as defined in claim 56

### Claim 65

A preserved product comprising a polypeptide or vaccine immunogen, one or more sugars and polyethylenimine, which product is in the form of an amorphous solid.

### Claim 66

A method of preparing a vaccine comprising a vaccine immunogen, which method comprises:
(a) providing an aqueous solution of one or more sugars, a polyethyleneimine and said vaccine immunogen wherein the concentration of polyethyleneimine is 15 μM or less based on the number-average molar mass (Mn) of the polyethyleneimine and the sugar concentration or, if more than one sugar is present, total sugar concentration is greater than 0.1M; and
(b) optionally adding an adjuvant, buffer, antibiotic and/or additive to the admixture; and drying the solution to form an amorphous solid matrix comprising said vaccine immunogen.

### Claim 67 (depends on 63)

A vaccine comprising a preserved product as defined in claim 63 and optionally an adjuvant.

### Claim 68 (depends on 64)

A vaccine comprising a preserved product as defined in claim 64 and optionally an adjuvant.

### Claim 69 (depends on 66)

A vaccine comprising a vaccine obtained by the method of claim 66 and optionally an adjuvant.

### Claim 70 (depends on 63)

A sealed vial, ampoule or syringe containing a dry powder as defined in claim 63.

### Claim 71 (depends on 64)

A sealed vial, ampoule or syringe containing a dry powder as defined in claim 64.

### Claim 72 (depends on 65)

A sealed vial, ampoule or syringe containing a preserved product as defined in claim 65.

### Claim 73 (depends on 67)

A sealed vial, ampoule or syringe containing a vaccine as defined in claim 67.

### Claim 74 (depends on 68)

A sealed vial, ampoule or syringe containing a vaccine as defined in claim 68.

### Claim 75 (depends on 69)

A sealed vial, ampoule or syringe containing a vaccine as defined in claim 69.
